Paper · 42806387

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study.

Fan Y and 18 others. Breast Cancer Res, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study. Papers, record 42806387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42806387

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study.
Journal: Breast Cancer Res
Year: 2026
Publication types: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed: https://pubmed.ncbi.nlm.nih.gov/42806387/
DOI: https://doi.org/10.1186/s13058-026-02339-z
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13617735/
The journal: https://conductscience.org/library/journal-index/100927353
Revised in PubMed: 2026-11-02

Source PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Fan Y	Ying
2	Ouyang Q	Quchang
3	Yin Y	Yongmei
4	Song L	Lihua
5	Wang X	Xiaojia
6	Li W	Wei
7	Li M	Man
8	Yan X	Xi
9	Wang S	Shusen
10	Sun T	Tao

1 to 10 of 19Source PubMed

See all 19 authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antibodies, Monoclonal, Humanized	Major topic
Immunoconjugates	Major topic
Triple Negative Breast Neoplasms	Major topic
Adult
Aged
Female
Humans
Middle Aged
Anemia
Neutropenia
Stomatitis
Thrombocytopenia
Treatment Outcome
Camptothecin

Source PubMed

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Stated by
2023-I2M-C & T-B-077	CAMS Innovation Fund for Medical Sciences	PubMed
2021-I2M-1-014	CAMS Innovation Fund for Medical Sciences	PubMed
CICAMS-MOMP202203	Major Project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences	PubMed
2025ZD0552504	Noncommunicable Chronic Diseases-National Science and Technology Major Project	PubMed
2025-LYZX-D-A02	National High Level Hospital Clinical Research Funding	PubMed

Source PubMed

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT05347134	SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer	Derived from the trial	Yes

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	37,296,177	Optimizing the safety of antibody-drug conjugates for patients with solid tumours.	Nat Rev Clin Oncol	2023	https://conductscience.org/library/papers/37296177	PubMed
2	35,614,462	Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer.	J Nanobiotechnology	2022	https://conductscience.org/library/papers/35614462	PubMed
3	40,947,843	Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort study.	Future Oncol	2025	https://conductscience.org/library/papers/40947843	PubMed
4	40,217,078	Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.	Nat Med	2025	https://conductscience.org/library/papers/40217078	PubMed
5	35,785,754	Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review.	Cancer Treat Rev	2022	https://conductscience.org/library/papers/35785754	PubMed
6	35,320,644	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.	N Engl J Med	2022	https://conductscience.org/library/papers/35320644	PubMed
7	33,552,868	Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance.	Adv Sci (Weinh)	2021	https://conductscience.org/library/papers/33552868	PubMed
8	34,664,433	An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers.	Adv Sci (Weinh)	2021	https://conductscience.org/library/papers/34664433	PubMed
9	36,620,535	Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.	Front Oncol	2022	https://conductscience.org/library/papers/36620535	PubMed
10	40,473,437	Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial.	BMJ	2025	https://conductscience.org/library/papers/40473437	PubMed

1 to 10 of 34

See all 34 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets
SACITUZUMAB TIRUMOTECAN	CHEMBL5314875	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL5314875

Source ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42806387

GET https://conductscience.org/api/papers/v1/42806387/references?page=2

API reference For AI assistants